Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
Records under this name other than the patents Nanjing Cavendish Bio-Engineering Technology Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 6 of 6 · Back to Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,884,013 | Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,108,954 | Synthesis process of dasatinib and intermediate thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,465,970 | Method for Synthesis of Roxadustat and Intermediate Compounds Thereof Formerly held Lapsed on the fee record Ended Oct 11, 2026 · High confidence | Lapsed on the fee record | Ended Oct 11, 2026 | High confidence |
| US 8,586,592 | Pharmaceutical formulations comprising voriconazole and processes for preparation thereof Lapsed on the fee record Ended Nov 19, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 19, 2025 | USPTO record |
| US 9,522,899 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Lapsed on the fee record Ended Dec 20, 2020 · USPTO record | Lapsed on the fee record | Ended Dec 20, 2020 | USPTO record |
| US 8,324,373 | Highly stereoselective process for preparing gemcitabine and intermediates thereof Lapsed on the fee record Ended Dec 4, 2020 · USPTO record | Lapsed on the fee record | Ended Dec 4, 2020 | USPTO record |